Qiagen (QGEN) and Myriad Genetics (MYGN) said Thursday they are working to develop a portable kit-based test for analyzing cancer patients' Homologous Recombination Deficiency status.
The test will combine Qiagen's QIAseq xHYB technology and digital insight product with Myriad's FDA-approved MyChoice CDx biomarkers, the companies said. It aims to assess multiple types of solid tumors, including ovarian cancer.
The project follows a previously announced partnership between the two companies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments